

Applicants: Tikva Vogel et al.
Serial No.: 09/492,971
Filed: January 27, 2000
Page 2

*Atty
Ondrade*

polypeptide has a molecular weight between about 12 and about 20 kD and] such polypeptide having an amino acid sequence which comprises at least one fifth of the amino acid sequence of the N-terminal [substantially the same as an amino acid sequence present in the] fibrin binding domain of naturally-occurring fibronectin, [and] wherein the imaging agent is capable of binding to fibrin.

REMARKS

Claims 88-96 were pending and under examination in the subject application. Applicants have hereinabove amended claim 88. Support for amended claim 88 can be found in the specification *inter alia* at page 51, lines 12-13 and page 60, lines 9-10. Therefore, applicants maintain that amended claim 88 does not raise any issue of new matter in connection with the subject application. Accordingly, applicants respectfully request entry of the amendment. Upon entry of the amendment, claims 88-96, as amended, will be pending and under examination.

INFORMATION DISCLOSURE STATEMENT

Applicants submit herewith an Information Disclosure Statement under 37 C.F.R. §1.56.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following disclosures:

1. U.S. Patent No. 4,315,906 to Gelder, issued February 16, 1982;
2. U.S. Patent No. 4,455,290 to Olexa et al., issued June 19, 1984;